INTRODUCTION
Many different terms are used to describe a variant allele's impact on enzyme function and the corresponding inferred phenotypic interpretation of a clinical pharmacogenetic test result. For example, a genetic testing laboratory report might interpret a TPMT *3A allele as leading to "low function, " "low activity, " "null allele, " "no activity, " or "undetectable activity. " Moreover, a laboratory might assign a phenotype designation to an individual carrying two nonfunctional TPMT alleles as being "TPMT homozygous deficient" while another laboratory might use the term "TPMT low activity. " These same labora tories could also use different terminology to describe a simi lar phenotype for a different gene (e.g., an individual carrying two nonfunctional DPYD alleles might be described as "DPYD defective"; see Supplementary Tables S1 and S2 online). As a result, the use of inconsistent terms can be confusing to clini cians, laboratory staff, and patients. Although the actual pheno types are the same in the TPMT and DPYD examples (i.e., no function), the terms describing these phenotypes have differed among laboratories and likely have led to confusion in the sub sequent interpretation.
The lack of standard vocabularies describing pharmacoge netic results also interferes with the exchange of structured inter pretations between laboratories, institutions using electronic health records (EHRs), and patients' personal health records. The impact on interoperability may significantly impede the portability of results throughout a patient's lifetime. [1] [2] [3] Recently, a joint guideline was developed by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) that standardized the interpre tation terms for describing the clinical significance of variants detected in Mendelian disease genes. 4 ClinGen has utilized these terms to enable comparison of interpretations from clini cal laboratories to identify and potentially resolve differences in variant interpretation, 5 a critical step in improving the unifor mity of patient care based on genetic information. Submitted Introduction: Reporting and sharing pharmacogenetic test results across clinical laboratories and electronic health records is a crucial step toward the implementation of clinical pharmacoge netics, but allele function and phenotype terms are not standard ized. Our goal was to develop terms that can be broadly applied to characterize pharmacogenetic allele function and inferred phe notypes.
Materials and methods:
Terms currently used by genetic testing laboratories and in the literature were identified. The Clinical Phar macogenetics Implementation Consortium (CPIC) used the Delphi method to obtain a consensus and agree on uniform terms among pharmacogenetic experts.
Results: Experts with diverse involvement in at least one area of pharmacogenetics (clinicians, researchers, genetic testing laborato rians, pharmacogenetics implementers, and clinical informaticians; n = 58) participated. After completion of five surveys, a consensus (>70%) was reached with 90% of experts agreeing to the final sets of pharmacogenetic terms.
Discussion:
The proposed standardized pharmacogenetic terms will improve the understanding and interpretation of pharmacogenetic tests and reduce confusion by maintaining consistent nomenclature. These standard terms can also facilitate pharmacogenetic data shar ing across diverse electronic health care record systems with clinical decision support.
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The Clinical Pharmacogenetics Implementation Consortium (CPIC) was formed in 2009 as a shared project between PharmGKB (https://www.pharmgkb.org) and the Pharmaco genomics Research Network (PGRN) (http://www.pgrn.org). CPIC provides clinical guidelines that enable the translation of pharmacogenetic laboratory test results into actionable prescrib ing decisions for specific drugs, 6 which to date has produced 17 clinical guidelines (https://cpicpgx.org/genesdrugs). Currently, the terms used in CPIC guidelines to describe allele function and phenotype reflect community usage for each gene and are there fore not standard across CPIC guidelines (Supplementary Table  S3 online). Ideally, phenotype terms should be easily interpretable by clinicians with basic pharmacogenetic training and, when pos sible, should be consistent across genes encoding proteins with similar functions (e.g., the use of the term "poor metabolizer" could describe an individual carrying two nonfunctional alleles for any drugmetabolizing enzyme).
To maximize the utility of pharmacogenetic test results and to facilitate more uniform implementation of CPIC guide lines, it is essential to standardize these terms. 7 To achieve this goal, particularly for purposes of clinical pharmacogenetic test reporting, CPIC initiated a project to identify terms that could be used consistently across pharmacogenes by developing a consensus among pharmacogenetics experts. The project par ticipants used a modified Delphi method, which is a structured approach to establishing consensus through iterative surveys of an expert panel. When possible, the goal was to agree on uniform terms that could be applied across pharmacogenes to characterize (i) allele functional status and (ii) inferred phe notypes based on the combined impact of both alleles (i.e., diplotypes).
MATeRIALS AND MeTHODS
The Delphi survey technique is an established approach to seek ing expert consensus on a topic. [8] [9] [10] The method uses a series of repeated structured questionnaires, or "rounds. " The rounds are usually anonymous and provide written, systematic refinement of expert opinion, and feedback of group opinion is provided after each round. 11 Delphi survey technique guidelines pro posed by Hasson et al. were consulted in the design of the proj ect. 12 The St. Jude Children's Research Hospital's institutional review board determined that this project does not meet the definition of research and was exempt from institutional review board purview.
For the Delphi method used (Figure 1) Experts not included in these groups were solicited by posting a description of the project on the PharmGKB website. All indi viduals who volunteered were included in survey 1.
Individuals were invited to participate in a series of surveys using an Internetbased survey tool (SurveyMonkey, Palo Alto, CA; http://www.surveymonkey.com) supplemented with live webinars that were used to explain the survey and solicit feed back. The webinars were designed to facilitate understanding of the survey to encourage completion; however, near the end of the process, an additional webinar was used to assist in develop ing a consensus. Each survey also included questions regarding the expert's workplace setting and degree of pharmacogenetic expertise (i.e., role in clinical pharmacogenetics and amount of time devoted to pharmacogenetics). Original research article
Responses were included in the analysis if the respondents provided their name and contact information, which were nec essary to enable followup with the respondents for the sub sequent round (trainees were not excluded). Responses were tabulated as numeric counts and frequencies for each phase to determine whether consensus was reached. Analyses were also performed to determine whether there were differences in responses based on the expert's role in clinical pharmaco genetics. These analyses tested clinician versus nonclinician responses using chisquared tests with an alpha of 0.05 to ensure that the final set of terms would be likely to be adopted by cli nicians as well as laboratorybased researchers. All analyses were conducted in R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria; http://www.Rproject.org).
The goal of this project was to standardize terms used to char acterize (i) allele functional status (i.e., allele descriptive terms) and (ii) inferred phenotypes based on the combined impact of both alleles (i.e., diplotypes). The terms used in the initial sur vey were identified by querying genetic testing laboratories and reviewing literature for currently used terms for CPIC Level A genes (https://cpicpgx.org/genesdrugs). This was informed by a literature review of references in the CPIC guidelines' evi dence tables and the terms used in these papers to describe allele function and clinical phenotypes for genes with current CPIC guidelines (i.e., CYP2D6, CYP2C19, CYP3A5, CYP2C9, TPMT, DPYD, HLA-B, UGT1A1, SLCO1B1, and VKORC1) (Supplementary Figures S1-S4 online). We also queried genetic testing laboratories listed at GeneTests (https://www. genetests.org/laboratories) and translational software compa nies and created a list of terms currently being used in labora tory reports.
For the first two survey rounds (surveys 1 and 2), terms that were found acceptable by at least 70% of the experts were retained for use in the next round. To improve semantic consis tency, terms that were retained after survey 1 were assembled into value sets, which together described the range of pos sible descriptors of alleles or phenotypes. These value sets were evaluated in surveys 2 through 4, and the top value sets were retained until 70% consensus was reached. For surveys 1 and 2, genes that encode enzymes with similar metabolic function were combined when appropriate (e.g., DPYD and TPMT were combined, as were all the CYP enzymes excluding CYP3A5) and experts were given the opportunity to suggest alternative terms. In survey 1, experts were also asked how many catego ries of function/phenotype they felt were needed (e.g., three major categories for TPMT-high/normal, medium/some, no activity, versus five major categories for CYP enzymes).
To promote consensus, a summary of comments from previ ous surveys was provided and experts were asked to read the comments prior to answering the questions (https://cpicpgx. org/resources/termstandardization). These comments were emphasized during the webinars to promote thoughtful discus sion. Experts also had access to the full survey results. Of note, experts from surveys 1 and 2 commented in the survey and during webinar discussions that the standardized terms should be consistent across all pharmacogenes if possible. Based on this feedback and feedback from CPIC members, three catego ries of value sets were proposed and grouped together in survey 3: (i) drugmetabolizing enzymes (all CYP enzymes, UGT1A1, DPYD, and TPMT), (ii) drug transporters (e.g., SLCO1B1) and non-drug metabolizing enzymes (e.g., VKORC1), and (iii) highrisk genotypes (e.g., HLAB). These groupings were used for the remainder of the surveys. Because consensus was not reached after survey 4, the experts were invited to participate in a conference call to discuss and recommend final terms, includ ing consideration of the potential disruptive impact of adopting a new term for clinical laboratories versus any anticipated ben efit of adopting a new term. These recommended terms were included in survey 5.
Although the Delphi method does not have a universal definition of consensus, 70% has been recommended and was considered a reasonable threshold given our diverse group of experts. 14, 15 Several new terms were added to survey 3 based on the feedback from rounds 1 and 2; these terms were built from existing terms and were included to improve semantic unifor mity within a value set (Supplementary Figures S1-S4 online) . The final survey (survey 5) measured the level of acceptance of the final sets of terms. Results from each round were posted on PharmGKB (https://cpicpgx.org/resources/termstandardiza tion) and were available to respondents throughout the process.
ReSULTS expert panel composition
A total of 222 individuals and approximately 2,000 subscrib ers to the CHAMP discussion board of AMP were invited to participate in the surveys; 58 completed survey 1, 54 completed survey 2, 47 completed survey 3, 46 completed survey 4, and 36 completed survey 5. The response group represented diverse involvement in at least one area of pharmacogenetics: 43% identified as clinicians, 67% as pharmacogenetics researchers, 19% as genetic testing laboratory staff, 43% as pharmacogenet ics implementers, and 12% as clinical informaticians. In addi tion, 86% of the participants were from the United States, 10% from Europe, and 3% from other countries (i.e., Brazil and Egypt). Individuals were permitted to selfidentify in more than one area; 48% of survey 1 respondents indicated that they spend >75% of their time devoted to pharmacogenetics, 57% of the experts were CPIC members, and 93% indicated they were involved in other pharmacogeneticrelated groups ( Table  1) . See Table 1 for additional demographics and numbers of experts for subsequent surveys. Phases 3-5: refinement and consensus. After survey 3, a consensus (77%) was reached for highrisk genotype genes but not for the other gene categories. Experts participating in survey 3 indicated that terms used to describe transporter function may not be suitable for all nondrugmetabolizing enzymes such as VKORC1 or genes encoding drug receptors. Thus, VKORC1 was excluded from future surveys (see "Discussion" for further explanation). Notably, assessing response rates between clinicians and nonclinicians did not reveal any significant differences (Supplementary Figure S5 online) .
At the conclusion of survey 4, one phenotype designation had not reached the targeted 70% consensus level. Although (24) 12 (22) 10 (21) 10 (22) 6 (17) Educational or research resource 9 (16) 7 (13) 6 (13) 6 (13) 5 (14) University 24 (41) 21 (39) 19 (40) 19 (41) 15 (42) Research or clinical institute 11 (19) 10 (19) 10 (22) 9 (20) 8 (22) Laboratory test interpretation service 6 (10) 4 (7) 3 (6) 3 (7) 3 (8)
Percentage of time devoted to pharmacogenetics 0-5% 3 (5) 1 (2) 1 (2) 1 (2) 1 (3) 6-26% 8 (14) 7 (13) 7 (15) 7 (15) 4 (11) 26-50% 8 (14) 6 (11) 5 (11) 5 (11) 7 (19) 51-75% 11 (19) 12 (22) 11 (23) 11 (24) 4 (11) 76-100% Original research article the phenotype designation of "intermediate metabolizer" was widely used in the literature to designate individuals between "normal metabolizer" and "poor metabolizer, " that term had not gained 70% consensus. After a conference call to discuss and recommend final terms to include in survey 5, and following completion of the final survey, 100% of experts agreed to terms for allele functional status for drugmetabolizing enzymes and transporters, 91.7% agreed to terms for drugmetabolizing enzyme phenotypes, and 91.7% agreed to terms for transporter phenotypes (Supplementary Figure S6 online) . The final terms and definitions are listed in Table 2 .
DISCUSSION
We successfully engaged a diverse group of experts to estab lish standard terms through consensus for both pharmacoge netic allele function and inferred phenotypes. The final terms presented in Table 2 will be used in all new and updated CPIC guidelines, and we recommend that these terms be considered standard terminology across all areas of clinical pharmacogenetics, including clinical genetic testing labora tory reporting. Moreover, these terms can be used for clinical decision support (CDS) to guide drug use and dosing (Table 3) using the suggested alerts in CPIC guidelines. [16] [17] [18] [19] In surveys 1 and 2 and during survey discussions, experts indicated that terms should be consistent across all genes if possible. Thus, terms describing phenotype were grouped together for subsequent surveys based on related enzyme functions. Final consensus terms included one set of terms to describe allele functional status and three sets of terms describ ing inferred phenotype depending on the type of pharmaco gene: (i) drugmetabolizing enzymes (e.g., CYP2D6, DYPD, and TPMT), (ii) transporters (e.g., SLCO1B1), and (iii) high risk genotypes (e.g., HLA-B) ( Table 2 ). These terms are suitable for use in most CPIC level A and B genes (https://cpicpgx.org/ genesdrugs).
Many experts felt that the historical and widely used term "extensive metabolizer" was too confusing for clinicians, often requiring clarification that it reflects "normal. " Therefore, the Original research article final consensus term "normal metabolizer" was selected, and "extensive metabolizer" will no longer be used in the CPIC guidelines. Furthermore, applying these standardized terms across all drugmetabolizing enzymes means that terms like "normal metabolizer" will also be used for genes such as TPMT and DPYD for which other designations were historically used (e.g., TPMT wildtype activity).
The speed with which we achieved consensus was based on the complexity of the gene and historical use of the term. Because of their simplicity and some level of standardization prior to this project, we quickly achieved consensus for the highrisk genotype genes (e.g., HLA-B). However, the phenotype terms describing drugmetabolizing enzymes were the most chal lenging to standardize owing to the different terms that have been used in research and clinical settings. Specifically, defining the term to distinguish the metabolizer status between "nor mal" and "poor" generated significant discussion. The panel eventually reached consensus on the commonly used term "intermediate metabolizer" after an additional review of the lit erature and after considering the difficulty of changing this spe cific term. Drugmetabolism terms often need to be interpreted considering the nature of the phenotypes relative to each other on a scale, going from very low function to very high function, which is more complex than expressing highrisk genotype genes as positive or negative for a specific variant allele. Visual depiction of such a scale (Figure 2 ) may be a helpful addition to interpretive reports.
Experts also had varying opinions about terms used to differ entiate between alleles for which there is no literature describ ing function and alleles for which there are conflicting data to support the resulting function. In survey 2, the choices of terms were identical for "no literature describing function" and "con flicting data, " and experts chose different terms for each type of variant. Although the distinction may not be immediately apparent to clinical providers, we speculate that the experts dif ferentiated these terms to be clear on the level and existence of evidence for a given variant. Distinguishing these concepts may provide value in certain contexts to distinguish lack of evidence from conflicting evidence, and this distinction may be emerg ing as a standard across genomic medicine (e.g., ClinVar). 20 Additional standardization opportunities exist beyond the genes presented here. For example, VKORC1 is the one CPIC level A gene (https://cpicpgx.org/genesdrugs) on which we did not reach a consensus. This gene is tested primarily in the con text of predicting starting doses of the common anticoagulant warfarin, which is also dependent on CYP2C9. Therefore, many laboratories report a drugcentered phenotype such as "greatly increased sensitivity to warfarin" (see the CPIC guideline for warfarin 21 ), which complicated standardization of VKORC1 terms following the formats used for other genes. In addition, VKORC1 genotype and inferred phenotypes for warfarin dosing are also reported by some laboratories and the CAP proficiency testing surveys according to the CYP2C9 and VKORC1 policy statement published by the ACMG in 2008, 22 which further could have added to the difficulty in standardizing VKORC1.
This project and recent work 13 have demonstrated that there is great diversity in how genetic test results are reported and interpreted, 23 which can lead to confusion among clinicians, patients, and researchers in the exchange and use of clinical genetic data. Clear opportunities exist to develop new terminol ogies and improve existing standards to represent genetic results and interpretations. 24 Although they do not represent compre hensive solutions, some progress has recently been made. An HL7 standard now exists that outlines how genetic test results could be reported. 25 The Logical Observation Identifier Names and Codes (LOINC) terminology, a widely used standard for reporting laboratory test results and interpretations, 26, 27 is one terminology that could be used to report genetic interpre tations, and it has recently been extended to support genetic data. 28 Therefore, to enable precise communication beyond the CPIC guidelines, encourage use of these terms within EHRs, and facilitate the implementation of pharmacogenetic CDS, we 29 Because pharmacogenetic expertise may remain concentrated in specialized healthcare centers but patients commonly move to and from a variety of healthcare providers, the consistent use of standard terms will improve the ability to share patientspecific pharmacogenetic knowledge across disparate clinical systems, including those systems with fewer resources for genomic medicine. In addition, the use of standard codes in CPIC guidelines to represent pharmacoge netic interpretation will facilitate further implementation of CDS rules, which are often triggered based on specific pharma cogenetic diagnoses with highrisk phenotypes. 29, 30 The Action Collaborative on Developing Guiding Principles for Integrating Genomic Information Into the Electronic Health Record Ecosystem (DIGITizE) (http://iom.nationalacademies. org/Activities/Research/GenomicBasedResearch/Innovation Collaboratives/EHR.aspx), an ad hoc activity under the aus pices of the Institute of Medicine Roundtable on Translating GenomicBased Research for Health, engages key stakeholders from health information technology and management ven dors, academic health centers, government agencies, and other organizations to work together to examine how genomic infor mation can be uniformly represented and integrated into EHRs in a standardsbased format. As an initial step, DIGITizE devel oped a CDS implementation guide for two pharmacogenetic use cases, HLA-B*57:01/abacavir and TPMT/azathioprine, based on the aforementioned HL7 standard and published CPIC guidelines. The implementation guide provides examples of HL7 messages for communicating the results of pharmaco genetic testing and CDS logic using the CPIC LOINC codes for HLA-B*57:01 and TPMT. As part of this effort, there was a careful decision to include only interpretations in the guide and not guidance for the genetic data itself. We anticipate that the availability of standard codes for pharmacogenetic interpreta tions will encourage the incremental development and dissemi nation of additional implementation resources.
In addition to facilitating LOINC implementation, another goal of CPIC is to have these standardized pharmacogenetic terms adopted broadly by clinical genetic testing laborato ries and relevant professional societies and organizations. Importantly, after reviewing the CPIC termstandardization project and outcome, the AMP, which is an international soci ety of more than 2,000 molecular and genomic laboratory medicine professionals, formally endorsed these pharmacoge netic terms on 26 October 2015 (http://www.amp.org/docu ments/AMPendorsementoftheCPICinitiative20151026.pdf). The terms from this study also may have significant utility for collaborative genomic variation curation and interpretation efforts, including ClinGen and ClinVar. 31 PharmGKB is cur rently working with ClinVar to deposit CPIC Level A gene/drug pairs using these standardized pharmacogenetic terms, and term adoption by other ClinVar submitters in the future would facilitate comparison across submissions. Additionally, these terms may be useful for proficiency testing programs that are designed to improve quality assurance and uniform pharmaco genetic interpretation among clinical genetic testing laboratories (e.g., College of American Pathologists (CAPPGX)). We chose to use a modified Delphi technique to build con sensus among pharmacogenetic experts because it is an estab lished and powerful tool to develop standards across different disciplines. 8, 9, 11 Key risks to the validity of a Delphi study include overestimating the expertise of participants and attrition across the consensus rounds. Given that each participant had involve ment in at least one area of pharmacogenetics and that 48% of survey 1 respondents indicated that they spend >75% of their time devoted to pharmacogenetics and 93% indicated they are involved with pharmacogeneticrelated groups, we feel this is adequate support of the pharmacogenetic expertise among our survey participants. Participant attrition did occur across con sensus rounds during our study; however, it was relatively low ( Table 1 ) and determined to be nonsystematic. Although only 60% of the experts participated in survey 5, relative to other Delphi panels and the recommended minimum panel size, our final consensus panel was quite large, which reinforces the valid ity of our results. 32 To reduce bias, especially the authority or rep utation of specific individuals, Delphi panel participants are often kept anonymous throughout the process. Although survey cre ators and analysts were not blinded to participants, identifying information was not shared among survey participants. The only points of participant identification were between surveys when nonblinded emails were used to send invitations to conference calls and webinars during which interim results were discussed.
Because these terms were established by experts, an opportunity for further research is to formally assess the terms in enduser usability studies to understand their com prehension among clinicians and patients without formal training or experience in pharmacogenetics. The clinicians' specific practice site may influence their view of these terms. Although surveys of general populations of physicians have indicated limited knowledge and experience with phar macogenetics 33, 34 and genomeguided prescribing through CDS, 35 a more recent study conducted in a setting with a preemptive pharmacogenetics testing program revealed that their physicians were supportive of this type of program and that pharmacogeneticguided therapy, particularly for car diovascular medications, has clinical utility. 36 Although our consensus terms were generated by experts, nearly 50% of our participants identified as clinicians, the use of terms by nonexpert clinicians and patients was considered through out the process, and most of our experts practice in clinical settings with nonexperts.
We aimed to achieve consensus on acceptable terms for multiple pharmacogenes. On their own, these terms may not always be an adequate interpretation to guide clinicians, and additional interpretation information can be provided to set the observed phenotype in the context of other possible pheno types. For example, with CYP enzymes, a normal metabolizer status would typically not trigger a dose that is different from that in the standard recommendation. However, in the case of tacrolimus, a CYP3A5 normal metabolizer (i.e., a CYP3A5 expresser) would require a higher recommended starting dose than the CYP3A5 poor metabolizer (a phenotype that is actu ally more common among those of European ancestry). 18 In practice, it will be necessary to provide a patient's phenotypic designation in combination with other interpretive informa tion designed for clinicians and patients, and various models of this approach already exist ( Table 3) . [37] [38] [39] In conclusion, we anticipate that broad adoption of these proposed standardized pharmacogenetic terms will improve the understanding and interpretation of pharmacogenetic tests by clinicians and patients and reduce confusion by maintaining nomenclature consistency among pharmaco genes. Furthermore, these uniform references will reduce the complexity of the underlying coded vocabulary needed to transmit pharmacogenetic phenotypes between indepen dent laboratories and sites of care and to trigger CDS.
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